Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial
Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial
Abstract Type III interferons have been touted as promising therapeutics in outpatients with coronavirus disease 2019 (COVID-19). We conducted a randomized placebo-controlled trial in 120 patients with mild to moderate COVID-19 to determine whether a single, 180 mcg subcutaneous dose of Peginterferon Lambda-1a (Lambda) could shorten the duration of viral shedding (primary endpoint) or symptoms (secondary endpoint, NCT04331899). In both the 60 patients receiving Lambda and the 60 receiving placebo, the median time to cessation of viral shedding was 7 days (hazard ratio [HR] = 0.81; 95% confidence interval [CI] 0.56 to 1.19). Symptoms resolved in 8 and 9 days in Lambda and placebo, respectively (HR 0.94; 95% CI 0.64 to 1.39). At enrollment; 41% of subjects were SARS-CoV-2 IgG seropositive; compared to placebo, lambda tended to delay shedding cessation in seronegatives (aHR 0.66, 95% CI 0.39-1.10) and to hasten shedding cessation in seropositives (aHR 1.58, 95% CI 0.88-2.86; p for interaction = 0.03). Liver transaminase elevations were more common in the Lambda vs. placebo arm (15/60 vs 5/60; p = 0.027). In this study, a single dose of subcutaneous Peginterferon Lambda-1a neither shortened the duration of SARS-CoV-2 viral shedding nor improved symptoms in outpatients with uncomplicated COVID-19.
Balasubramanian Vidhya、Singh Upinder、Andrews Jason R.、Jacobson Karen B.、Purington Natasha、de Vries Christiaan R.、Ley Catherine、Winslow Dean、Edwards Karlie、Glenn Jeffrey、Wang Taia、Desai Manisha、Parsonnet Julie、Khosla Chaitan、Maldonado Yvonne、Kamble Savita、Blish Catherine、Newberry Jennifer、Hislop Colin、Choong Ingrid、Bhatt Ami、Quintero Orlando、Feng Kent、Hedlin Haley、Pinsky Benjamin A.、Bonilla Hector、Jagannathan Prasanna
Quantitative Sciences Unit, Stanford UniversityDepartment of Medicine, Stanford University||Department of Microbiology and Immunology, Stanford UniversityDepartment of Medicine, Stanford UniversityDepartment of Medicine, Stanford UniversityQuantitative Sciences Unit, Stanford UniversityDepartment of Medicine, Stanford UniversityDepartment of Medicine, Stanford UniversityDepartment of Medicine, Stanford UniversityDepartment of Medicine, Stanford UniversityDepartment of Medicine, Stanford University||Department of Microbiology and Immunology, Stanford UniversityDepartment of Medicine, Stanford University||Department of Microbiology and Immunology, Stanford UniversityQuantitative Sciences Unit, Stanford UniversityDepartment of Medicine, Stanford UniversityChEM-H, Stanford UniversityEiger BioPharmaceuticalsStanford Center for Clinical Research, Stanford UniversityDepartment of Medicine, Stanford UniversityDepartment of Emergency Medicine, Stanford UniversityDepartment of Pediatrics, Stanford UniversityDepartment of Pediatrics, Stanford UniversityDepartment of Medicine, Stanford University||Department of Genetics, Stanford UniversityDepartment of Medicine, Stanford UniversityStanford Center for Clinical Research, Stanford UniversityQuantitative Sciences Unit, Stanford UniversityDepartment of Medicine, Stanford University||Department of Pathology, Stanford UniversityDepartment of Medicine, Stanford UniversityDepartment of Medicine, Stanford University||Department of Microbiology and Immunology, Stanford University
医学研究方法临床医学基础医学
Balasubramanian Vidhya,Singh Upinder,Andrews Jason R.,Jacobson Karen B.,Purington Natasha,de Vries Christiaan R.,Ley Catherine,Winslow Dean,Edwards Karlie,Glenn Jeffrey,Wang Taia,Desai Manisha,Parsonnet Julie,Khosla Chaitan,Maldonado Yvonne,Kamble Savita,Blish Catherine,Newberry Jennifer,Hislop Colin,Choong Ingrid,Bhatt Ami,Quintero Orlando,Feng Kent,Hedlin Haley,Pinsky Benjamin A.,Bonilla Hector,Jagannathan Prasanna.Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial[EB/OL].(2025-03-28)[2025-05-12].https://www.medrxiv.org/content/10.1101/2020.11.18.20234161.点此复制
评论